MDFEM

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

MDFEM, also known as 4-(2,2-difluoroethoxy)-2,5-dimethoxyamphetamine, is a serotonin receptor modulator of the phenethylamine, amphetamine, and DOx families. It is a derivative of the DOx psychedelics TMA-2 and MEM in which the 4-position substituent has been extended. The properties and effects of MDFEM in humans appear to be unknown. The drug is a partial agonist of the serotonin 5-HT 2A and 5-HT 2B receptors and also shows other receptor interactions. MDFEM was first described in the scientific literature by Daniel Trachsel by 2012.

MDFEM, also known as 4-(2,2-difluoroethoxy)-2,5-dimethoxyamphetamine, is a serotonin receptor modulator of the phenethylamine, amphetamine, and DOx families. It is a derivative of the DOx psychedelics TMA-2 and MEM in which the 4-position substituent has been extended. The properties and effects of MDFEM in humans appear to be unknown. The drug is a partial agonist of the serotonin 5-HT 2A and 5-HT 2B receptors and also shows other receptor interactions. MDFEM was first described in the scientific literature by Daniel Trachsel by 2012.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1349210631 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.